Literature DB >> 1455397

Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.

M Jurado1, J A Páramo, M Gutierrez-Pimentel, E Rocha.   

Abstract

We studied the fibrinolytic response before and after venous occlusion (VO) in 30 patients with systemic lupus erythematosus (SLE), 25 with rheumatoid arthritis (RA) and 25 with different connective tissue disorders. Results were compared in patients with and without antiphospholipid antibodies (APA) and a history of either thrombosis or abortions. Before occlusion plasma levels of tissue-type plasminogen activator (t-PA) antigen and its inhibitor (PAI-1) were significantly higher in the patient group (p < 0.001). After occlusion, a low fibrinolytic activity on fibrin plates (p < 0.005) was observed in the same group. t-PA capacity and t-PA release were similar in relation to controls. The plasma PAI-1 activity was significantly elevated in each group of patients (p < 0.005) as compared to the control group. No significant differences with respect to t-PA and PAI-1 were observed in patients as to the presence or absence of thrombosis. There was also no correlation between the fibrinolytic changes and the presence of APA. It is concluded that an impairment of the fibrinolytic system, mainly related to increased PAI-1 levels, is present in most patients with connective tissue disorders, although these changes did not correlate with the presence of APA or the incidence of thrombosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455397

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

Review 1.  Impaired fibrinolysis in the antiphospholipid syndrome.

Authors:  Katie A Krone; Kristi L Allen; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 2.  The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis.

Authors:  Ewa Olech; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

3.  Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.

Authors:  A Doria; A Ghirardello; M Boscaro; M L Viero; E Vaccaro; G M Patrassi; P F Gambari
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

4.  Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

Authors:  T Atsumi; M A Khamashta; O Amengual; S Donohoe; I Mackie; K Ichikawa; T Koike; G R Hughes
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

5.  Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome.

Authors:  V Salle; J C Mazière; A Smail; R Cévallos; C Mazière; V Fuentes; B Tramier; R Makdassi; G Choukroun; O Vittecoq; V Goëb; J P Ducroix
Journal:  J Clin Immunol       Date:  2008-03-06       Impact factor: 8.317

6.  Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.

Authors:  N K Singh; A Gupta; Dibya R Behera; D Dash
Journal:  Rheumatol Int       Date:  2013-03-22       Impact factor: 2.631

7.  Pathogenesis of Antiphospholipid Syndrome.

Authors:  Borut Bo Ic
Journal:  EJIFCC       Date:  2004-08-31

Review 8.  Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.

Authors:  Jason S Knight; Yogendra Kanthi
Journal:  Semin Immunopathol       Date:  2022-02-04       Impact factor: 11.759

9.  Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus.

Authors:  Rustem I Litvinov; Rosa M Nabiullina; Laily D Zubairova; Mileusha A Shakurova; Izabella A Andrianova; John W Weisel
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.